002294 信立泰
已收盘 09-11 15:00:00
资讯
新帖
简况
信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧
蓝鲸财经 · 09-10
信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧
8家公司递表，梅卡曼德刷新年内板块认购纪录
同花顺 · 09-07
8家公司递表，梅卡曼德刷新年内板块认购纪录
股市必读：信立泰新发布《关于向香港联交所递交H股发行上市申请并刊发申请资料的进展公告》
证券之星 · 09-07
股市必读：信立泰新发布《关于向香港联交所递交H股发行上市申请并刊发申请资料的进展公告》
仿制药业务持续萎缩，信立泰再次递表港交所
同花顺 · 09-04
仿制药业务持续萎缩，信立泰再次递表港交所
信立泰再次递表港交所 深耕心肾代谢综合征疾病治疗领域
同花顺 · 09-04
信立泰再次递表港交所 深耕心肾代谢综合征疾病治疗领域
【新股IPO】信立泰药业向港交所主板递交上市申请 拟实现A+H上市
金吾财讯 · 09-03
【新股IPO】信立泰药业向港交所主板递交上市申请 拟实现A+H上市
信立泰(002294.SZ)向香港联交所更新递交H股发行上市申请并刊发申请资料
智通财经 · 09-03
信立泰(002294.SZ)向香港联交所更新递交H股发行上市申请并刊发申请资料
信立泰（002294）披露回购公司股份进展公告，9月2日股价下跌1.29%
证券之星 · 09-02
信立泰（002294）披露回购公司股份进展公告，9月2日股价下跌1.29%
信立泰：截至8月31日公司累计回购股份7090040股
证券日报 · 09-02
信立泰：截至8月31日公司累计回购股份7090040股
股市必读：信立泰中报 - 第二季度单季净利润同比下降1.78%
证券之星 · 08-26
股市必读：信立泰中报 - 第二季度单季净利润同比下降1.78%
信立泰（002294）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-26
信立泰（002294）2026年中报简析：营收净利润同比双双增长
图解信立泰中报：第二季度单季净利润同比下降1.78%
证券之星 · 08-25
图解信立泰中报：第二季度单季净利润同比下降1.78%
8月21日信立泰跌5.36%，光大健康优加混合A基金重仓该股
证券之星 · 08-21
8月21日信立泰跌5.36%，光大健康优加混合A基金重仓该股
信立泰（002294）披露SAL012药品临床试验申请获得受理的公告，8月14日股价下跌2.51%
证券之星 · 08-14
信立泰（002294）披露SAL012药品临床试验申请获得受理的公告，8月14日股价下跌2.51%
信立泰最新公告：SAL012临床试验申请获受理
证券之星 · 08-14
信立泰最新公告：SAL012临床试验申请获受理
新股消息 | 信立泰(002294.SZ)港股IPO招股书失效
智通财经 · 08-12
新股消息 | 信立泰(002294.SZ)港股IPO招股书失效
信立泰（002294）披露SAL0195获得临床试验批准通知书，8月7日股价上涨6.44%
证券之星 · 08-07
信立泰（002294）披露SAL0195获得临床试验批准通知书，8月7日股价上涨6.44%
信立泰最新公告：SAL0195获临床试验批准通知书
证券之星 · 08-07
信立泰最新公告：SAL0195获临床试验批准通知书
信立泰（002294）披露回购公司股份进展公告，8月3日股价下跌0.24%
证券之星 · 08-03
信立泰（002294）披露回购公司股份进展公告，8月3日股价下跌0.24%
7月21日信立泰跌5.44%，金信价值精选混合A基金重仓该股
证券之星 · 07-21
7月21日信立泰跌5.44%，金信价值精选混合A基金重仓该股
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物及医疗器械、骨科药物、头孢类抗生素及原料。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":30.07,"timestamp":1789110207000,"preClose":31.04,"halted":0,"volume":12187340,"delay":0,"changeRate":-0.0312,"floatShares":1115000000,"shares":1115000000,"eps":0.6042,"marketStatus":"已收盘","change":-0.97,"latestTime":"09-11 15:00:00","open":30.8,"high":30.87,"low":30.01,"amount":368000000,"amplitude":0.0277,"askPrice":30.07,"askSize":265,"bidPrice":30.06,"bidSize":577,"shortable":0,"etf":0,"ttmEps":0.6042,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":31.04,"symbolType":"stock","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":34.14,"lowLimit":27.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":4.04,"roa":"--","peRate":49.768289,"roe":"4.3%","epsLYR":0.58,"committee":0.686118,"marketValue":33523000000,"turnoverRate":0.0109,"status":1,"floatMarketCap":33515000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2666648561","title":"信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666648561?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面，信立泰转型取得阶段性成果的同时，核心产品收入集中的风险始终悬而未决。作为转型最重要的产品，信立坦2024 年销售额约 15 亿元，是公司创新药板块最主要的收入来源，公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保，形成产品梯队，但是这些新产品体量尚小，短期内难以替代信立坦的收入贡献，公司仍然处于单品依赖阶段。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4127","159992","FRHC","IBBQ","BK1574","LNGR","BK0028","BK0196","BK1161","BK0188","002294","06978","BK0239","KCE","BK0187","BK0183","REDS","MEDX","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665663318","title":"8家公司递表，梅卡曼德刷新年内板块认购纪录","url":"https://stock-news.laohu8.com/highlight/detail?id=2665663318","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665663318?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:37","pubTimestamp":1788770220,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者吴歌 Wind数据显示，8月31日—9月6日有8家公司向港交所递表，另有1家公司通过聆讯，3家公司招股及2只新股上市。从行业分布看，递表企业覆盖高端制造、车载光学、生物医药 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260907/c679658502.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260907/c679658502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0183","BK0188","BK0196","002294","BK0187","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665736788","title":"股市必读：信立泰新发布《关于向香港联交所递交H股发行上市申请并刊发申请资料的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2665736788","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665736788?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:31","pubTimestamp":1788715867,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，信立泰报收于31.42元，下跌0.16%，换手率0.78%，成交量8.64万手，成交额2.73亿元。公司公告汇总：信立泰于2026年9月3日更新并向香港联交所刊发H股发行上市申请的更新版草拟资料。交易信息汇总资金流向9月4日主力资金净流入117.22万元，占总成交额0.43%；游资资金净流出1207.53万元，占总成交额4.42%；散户资金净流入1090.31万元，占总成交额3.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0188","BK0183","BK0196","BK0187","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382935","title":"仿制药业务持续萎缩，信立泰再次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382935","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664382935?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:23","pubTimestamp":1788506580,"startTime":"0","endTime":"0","summary":"已在A股上市17年的心血管龙头深圳信立泰药业股份有限公司，近日再次递表港交所。公开信息显示，这家年收入已突破43亿元、净利润超过6.5亿元的老牌药企增长正在切换引擎，仿制药业务持续萎缩 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260904/c679603764.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260904/c679603764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0187","002294","BK0239","BK0183","BK0028","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382344","title":"信立泰再次递表港交所 深耕心肾代谢综合征疾病治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382344","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664382344?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:12","pubTimestamp":1788505920,"startTime":"0","endTime":"0","summary":"据港交所9月3日披露，深圳信立泰药业股份有限公司(简称：信立泰，002294.SZ)向港交所主板递交上市申请书，高盛、花旗、中信证券为其联席保荐人。该公司曾于2月12日递表港交所。公司简介据招 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260904/c679603409.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260904/c679603409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002294","BK0183","BK0239","BK0028","BK0188","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664035188","title":"【新股IPO】信立泰药业向港交所主板递交上市申请 拟实现A+H上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664035188","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664035188?lang=zh_cn&edition=full","pubTime":"2026-09-03 23:33","pubTimestamp":1788449639,"startTime":"0","endTime":"0","summary":"金吾财讯 ｜ 据港交所9月3日文件披露，深圳信立泰药业股份有限公司向港交所主板递交上市申请书，拟实现A+H两地上市，联席保荐人为高盛、花旗、中信证券。弗若斯特沙利文数据显示，按2025年国内心血管药物院内销售收入统计，信立泰位列国内第二，市场份额11.3%；以心肾代谢综合征领域已上市NME以及进入IND阶段或之后的候选药物数量统计，公司在国内药企中排名第二。","market":"nz","thumbnail":"https://static.szfiu.com/news/20220324/MzRhMTE1MTUwMjgzODI3Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/MzRhMTE1MTUwMjgzODI3Nw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990636","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002294","HEXmain","BK0196","BK0183","BK0239","BK0188","KCE","IPOS","BK4127","BK0028","REDS","BK0187","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664713688","title":"信立泰(002294.SZ)向香港联交所更新递交H股发行上市申请并刊发申请资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2664713688","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664713688?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:40","pubTimestamp":1788435630,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，公司正在进行申请发行境外上市股份(H股)并在香港联合交易所有限公司(下称“香港联交所”)主板挂牌上市的相关工作。根据本次发行上市计划及香港联交所的相关要求，公司于2026年9月3日向香港联交所更新递交了本次发行上市的申请，并于同日在香港联交所网站刊登了本次发行上市的更新申请资料。该申请材料为公司按照香港证券及期货事务监察委员会及香港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新及修订。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294","BK0188","BK0183","BK0196","BK0187","IPOS","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817175","title":"信立泰（002294）披露回购公司股份进展公告，9月2日股价下跌1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817175","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664817175?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:20","pubTimestamp":1788358825,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，信立泰报收于31.46元，较前一交易日下跌1.29%，最新总市值为350.72亿元。该股当日开盘31.89元，最高31.9元，最低31.41元，成交额达3.11亿元，换手率为0.88%。近日，信立泰发布《关于回购公司股份的进展公告》。本次回购符合相关法规及既定方案要求，后续将根据市场情况继续实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200042876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0183","BK0239","BK0028","BK0188","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664981470","title":"信立泰：截至8月31日公司累计回购股份7090040股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664981470","media":"证券日报 ","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664981470?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:13","pubTimestamp":1788351180,"startTime":"0","endTime":"0","summary":"9月2日，信立泰发布公告称，截至2026年8月31日，公司通过回购专用证券账户以集中竞价交易方式回购公司股份7，090，040股，占公司目前总股本的0.64%，最高成交价为40.80元/股，最低成交价为29.28元/股，成交总金额为22，780.73万元（不含交易费用）。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-02/doc-iniqmwqu2789331.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-02/doc-iniqmwqu2789331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","BK0028","BK0188","BK0196","BK0239","002294","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662768286","title":"股市必读：信立泰中报 - 第二季度单季净利润同比下降1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662768286","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662768286?lang=zh_cn&edition=full","pubTime":"2026-08-26 07:24","pubTimestamp":1787700255,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年上半年归母净利润3.87亿元，同比上升6.03%；第二季度单季度归母净利润1.62亿元，同比下降1.78%。股本股东变化股东户数变动截至2026年6月30日公司股东户数为7.41万户，较3月31日增加4.87万户，增幅为192.0%；户均持股数量由上期的4.39万股减少至1.5万股，户均持股市值为47.97万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600012395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662575067","title":"信立泰（002294）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2662575067","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662575067?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:23","pubTimestamp":1787696586,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期信立泰发布2026年中报。根据财报显示，信立泰营收净利润同比双双增长。截至本报告期末，公司营业总收入24.79亿元，同比上升16.34%，归母净利润3.87亿元，同比上升6.03%。持有信立泰最多的基金为光大健康优加混合A，目前规模为6.23亿元，最新净值0.8565，较上一交易日上涨1.65%，近一年下跌13.11%。本文数据来源于信立泰2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600009908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662039582","title":"图解信立泰中报：第二季度单季净利润同比下降1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662039582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662039582?lang=zh_cn&edition=full","pubTime":"2026-08-25 02:23","pubTimestamp":1787595799,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰2026年中报显示，上半年度公司主营收入24.79亿元，同比上升16.34%；归母净利润3.87亿元，同比上升6.03%；扣非净利润4.01亿元，同比上升15.64%；其中2026年第二季度，公司单季度主营收入12.51亿元，同比上升17.02%；单季度归母净利润1.62亿元，同比下降1.78%；单季度扣非净利润1.8亿元，同比上升16.07%；负债率21.52%，投资收益1508.84万元，财务费用721.07万元，毛利率75.09%。财报数据概要请见下图:本文数据来源于信立泰2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500005359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661265227","title":"8月21日信立泰跌5.36%，光大健康优加混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661265227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661265227?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:44","pubTimestamp":1787301841,"startTime":"0","endTime":"0","summary":"证券之星消息，8月21日信立泰跌5.36%，收盘报32.68元，换手率2.76%，成交量30.78万手，成交额10.1亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为光大保德信基金的光大健康优加混合A。光大健康优加混合A目前规模为6.23亿元，最新净值0.8996，较上一交易日上涨4.04%，近一年下跌4.91%。光大健康优加混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100029597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0188","BK0028","BK0183","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147891","title":"信立泰（002294）披露SAL012药品临床试验申请获得受理的公告，8月14日股价下跌2.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147891?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:03","pubTimestamp":1786716201,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，信立泰报收于34.9元，较前一交易日下跌2.51%，最新总市值为389.07亿元。该股当日开盘35.2元，最高36.07元，最低34.29元，成交额达11.42亿元，换手率为2.92%。近日，深圳信立泰药业股份有限公司及全资子公司收到国家药品监督管理局出具的受理通知书，公司自主研发的创新药“注射用SAL012”临床试验申请已获受理。该药品为1类治疗用生物制品，拟用于治疗晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400039502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0028","BK0188","BK0196","BK0239","002294","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659011792","title":"信立泰最新公告：SAL012临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2659011792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659011792?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:26","pubTimestamp":1786699617,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司及全资子公司收到国家药品监督管理局出具的受理通知书，自主研发的1类创新药“注射用SAL012”临床试验申请获得受理。该药品为治疗用生物制品，用于治疗晚期实体瘤。临床前研究显示，SAL012具有剂量依赖性抑制肿瘤生长的潜力，安全性、耐受性良好。若研发成功并获批上市，将为晚期实体瘤患者提供新的用药选择。该产品短期内对公司业绩不会产生实际影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400029155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002294","BK0196","BK0188","BK0239","BK0187","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658094925","title":"新股消息 | 信立泰(002294.SZ)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2658094925","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658094925?lang=zh_cn&edition=full","pubTime":"2026-08-12 06:35","pubTimestamp":1786487738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，深圳信立泰药业股份有限公司于2026年2月12日所递交的港股招股书满6个月，于2026年8月12日失效，递表时高盛、花旗、中信证券为其联席保荐人。据此前招股书，信立泰是中国心血管-肾脏-代谢疾病治疗领域的先行者。截至最后实际可行日期，根据弗若斯特沙利文的资料，公司拥有按规模计国内企业中第二大的心肾代谢综合征创新药管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FRHC","BK4585","BK0188","VXUS","KCE","BK4127","BK0183","BK4588","KCAI","REDS","BK0239","BK0196","IPOS","002294","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657564175","title":"信立泰（002294）披露SAL0195获得临床试验批准通知书，8月7日股价上涨6.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657564175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657564175?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:04","pubTimestamp":1786111462,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，信立泰报收于36.03元，较前一交易日上涨6.44%，最新总市值为401.67亿元。该股当日开盘33.81元，最高36.08元，最低33.8元，成交额达14.42亿元，换手率为3.69%。近日，深圳信立泰药业股份有限公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新siRNA药物SAL0195注射液开展治疗脂蛋白增高的临床试验。公司将按相关规定开展临床试验，后续进展将及时披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700040492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","002294","BK0028","BK0239","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657123246","title":"信立泰最新公告：SAL0195获临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657123246","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657123246?lang=zh_cn&edition=full","pubTime":"2026-08-07 18:10","pubTimestamp":1786097423,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司收到国家药监局核准签发的《临床试验批准通知书》，同意公司自主研发的创新siRNA药物SAL0195注射液开展治疗脂蛋白(a)增高的临床试验。该药物在临床前猴模型中具有单次给药持续140天的靶点敲除长效作用，有望为患者提供新的用药选择，并丰富公司慢病领域创新产品管线。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700033511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0187","BK0196","BK0183","BK0188","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656724372","title":"信立泰（002294）披露回购公司股份进展公告，8月3日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656724372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656724372?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:09","pubTimestamp":1785766157,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，信立泰报收于33.2元，较前一交易日下跌0.24%，最新总市值为370.12亿元。该股当日开盘33.28元，最高33.65元，最低33.01元，成交额达4.96亿元，换手率为1.34%。近日，信立泰发布关于回购公司股份的进展公告。公告显示，公司于2026年5月29日召开董事会，审议通过回购公司股份的议案，拟以自有资金及自筹资金回购A股股份，资金总额不低于30,000万元且不超过50,000万元，回购价格不超过45元/股。回购股份用于股权激励或员工持股计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300036810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002294","BK0196","BK0187","BK0239","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653220235","title":"7月21日信立泰跌5.44%，金信价值精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653220235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653220235?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:47","pubTimestamp":1784623662,"startTime":"0","endTime":"0","summary":"证券之星消息，7月21日信立泰跌5.44%，收盘报35.28元，换手率5.23%，成交量58.26万手，成交额20.4亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为金信基金的金信价值精选混合A。金信价值精选混合A目前规模为0.17亿元，最新净值1.9273，较上一交易日上涨3.56%，近一年上涨114.44%。金信价值精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100030848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","BK0239","BK0196","002294","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789344284478,"stockEarnings":[{"period":"1week","weight":-0.043},{"period":"1month","weight":-0.1479},{"period":"3month","weight":-0.0393},{"period":"6month","weight":-0.4168},{"period":"1year","weight":-0.4359},{"period":"ytd","weight":-0.3834}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"74115人(较上一季度增加192.00%)","perCapita":"15038股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物及医疗器械、骨科药物、头孢类抗生素及原料。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}